No Data
No Data
Asymchem Laboratories (Tianjin) Repurchases, Cancels 17.5 Million A Shares
Asymchem Laboratories (06821) has completed the repurchase and cancellation of a total of 1.7534 million restricted A shares.
Asymchem Laboratories (06821) announced that as of the date of this announcement, a total of 1.7534 million shares have been repurchased and cancelled.
Asymchem Laboratories (06821) announced on August 14th that it would spend 225 million yuan to repurchase 1.7534 million A shares.
Asymchem Laboratories (06821) announced that on August 14, 2024, the company will spend CNY 0.225 billion to repurchase 1...
Asymchem Laboratories (06821.HK) was reduced by JPMorgan by 0.1623 million shares.
According to the latest equity disclosure information from the Hong Kong Stock Exchange, on August 7, 2024, JPMorgan Chase & Co. reduced its shareholding of Asymchem Laboratories (06821.HK) by selling 0.1623 million shares at an average price of HKD 47.8356 per share, involving approximately HKD 7.7637 million. After the reduction, JPMorgan Chase & Co.'s latest shareholding is 1.5738 million shares, and the shareholding ratio has decreased from 6.30% to 5.71%.
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
No Data